Leukeran Indication:

For treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease

Leukeran Mechanism Of Action:

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Leukeran Drug Interactions:

Not Available

Leukeran Food Interactions:

Take on an empty stomach.
Drink liberally.
Food reduces bioavailability.

Leukeran Generic Name:

Synonyms:

  • Chloraminophen
  • Chloraminophene
  • Phenylbutyric Acid Nitrogen Mustard
  • Chlorobutine
  • Chlorobutin
  • Chloroambucil
  • Chlorbutine
  • Chlorbutin
  • Chlocambucil

Drug Type:

Small Molecule; Approved

Absorption:

Not Available

Toxicity (Overdose):

Not Available

Protein Binding:

99%

Biotransformation:

Not Available

Half Life:

1.5 hours

Dosage Forms of Leukeran:

Tablet Oral

Chemical IUPAC Name:

4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid

Organisms Affected:

Humans and other mammals

Leukeran to general, pharmacology

General, pharmacology..
Cancer